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 Computed tomography (CT) and magnetic resonance (MR) enterography have emerged 
as the most effective methods for imaging the small bowel in patients with Crohn’s disease 1, 2.  
Cross sectional enterography techniques complement ileocolonoscopy and can visualize 
intramural or proximal small bowel inflammation in approximately 50% of Crohn’s disease 
patients who have endoscopically normal exams 
3-5
.  CT and MR enterography are useful tools 
for Crohn’s disease diagnosis, determining distribution of disease involvement, and detecting 
complications of the disease 
1, 2
.  Recent data suggest that cross sectional imaging may be useful 
in determining response to therapy, assessing bowel healing, and monitoring disease progression 
6
.  The Society for Abdominal Radiology (SAR) formed a Crohn’s Disease-focused panel, which 
has established guidelines for the technical performance of these examinations 
7, 8
.  CT and MR 
enterography are now performed across a range of institutions, with the radiologic literature 
focusing on the technical aspects of diagnosis and grading of mural inflammation or penetrating 
complications, such as fistula and abscess, using various acquisition methods and imaging 
findings.  Important prior consensus statements including those of the European Crohn’s and 
Colitis Organization and European Society of Gastrointestinal and Abdominal Radiology and 
SAR recommendations for the performance of CT and MR enterography establish critical and 
necessary rationale for when and how imaging of inflammatory bowel disease patients should be 
performed, respectively 
2, 7, 8
. To date, however, there are no agreed upon expectations for 
structures that should be evaluated at cross-sectional enterography, no standardized 
nomenclature for describing imaging findings in Crohn’s disease, no guidance for how to 
describe severity and burden of different Crohn’s disease imaging findings to best guide medical 
and surgical management, and no consensus between U.S. gastroenterology and radiology 
  
societies on when these tests should be performed.  The purpose of this work is to establish a 
common system for mapping specific imaging findings to clinically useful impressions and for 
description of Crohn’s disease phenotypes that can guide gastroenterologists and surgeons in 
making important treatment decisions for Crohn’s disease patients.  The standardization will 
both advance patient care through improved understanding of the communicated imaging 
findings and improve comparison of reported research in the field. 
 Because CT and MR enterography findings change patient management in a substantial 
proportion of symptomatic patients 
9, 10
, systematic review of CT and MR enterography images is 
essential to maximize patient benefit.  A motivating example for how a systematic review of 
imaging findings and standard nomenclature might improve patient care can be found in the 
standard reporting template for pancreatic cancer:  an interdisciplinary group of radiologists, 
medical oncologists, pancreatologists and pancreatic surgeons recommended a systematized 
reporting template for pancreatic carcinoma, designed to capture objective imaging findings to 
guide and improve therapeutic decisions 
11
.   In Crohn’s disease, the use of imaging is evolving 
over time.  Cross-sectional imaging was initially used to detect and stage Crohn’s disease 5, but it 
is increasingly being used to gauge therapeutic response 
4, 12
, providing objective measures to 
guide treatment decisions that can potentially alter the natural history of the disease 
13
.  Mucosal 
healing as detected by colonoscopy in Crohn’s disease results in improved outcome 14-17; 
however, more recently cross-sectional imaging, primarily MR enterography, has demonstrated a 
high correlation between mucosal healing at endoscopy and mural healing at cross-sectional 
imaging, with improved outcomes when detected 
18-20
.  Thus, there needs to be a shared 
understanding of the goals of imaging between referring clinicians and radiologists:  while 
numerous investigators have consequently examined the relationship between objective and 
  
subjective imaging findings and the severity of endoscopic and histologic inflammation 
4, 21-24
,  
others have described the extent of intestinal damage using cross-sectional findings 
25
.  
Information conveying length of involvement, severity of inflammation or bowel dilatation, and 
surgical resections are required when assessing for therapeutic response.   
While the existing Montreal classification (and pediatric Paris classification) sub-classify 
phenotypes of Crohn’s disease, including non-stricturing and non-penetrating inflammatory 
disease, stricturing disease, penetrating complications and perianal fistula 
26, 27
, they do not 
describe the length and severity of inflammatory involvement or the anatomic relationship of co-
existing phenotypes that are necessary to make important surgical and medical management 
decisions.  More specifically, the Montreal/Paris classifications do not take into account the 
dynamic, continuum of the disease, the overlap or co-existence of stricturing and penetrating 
disease (two separate types of disease complications occurring from disease progression) 
28, 29
, as 
well as the fact that active inflammation is most often present in stricturing complications 
21, 28, 30
.  
Both CTE and MRE can detect the morphologic continuum and co-existing “complications” with 
regularity, thus prompting the need for radiologists to reliably define and reproducibly describe 
the anatomic burden of inflammation and Crohn’s disease complications. 
These guidelines define imaging findings that should be evaluated, how disease burden 
should be described, and pathophysiologic conclusions that will improve the ability of 
gastroenterologists and intestinal surgeons to best make management decisions.  For example, 
radiologists should examine for Crohn’s disease strictures, which are defined in this guideline as 
small bowel segments with luminal narrowing and unequivocal proximal (upstream) dilation.  
Moreover, these guidelines emphasize that when strictures are found, the length of the stricture 
and radiologic findings of concurrent inflammation and obstruction should be described.  These 
  
elements provide much of the critical information a gastroenterologist will need to consider in 
determining options for medical, surgical or endoscopic therapy.  The benefits of a shared 
understanding and improved communication of cross-sectional enterography exams will 
facilitate:   
 Improved use of imaging to guide treatment options, and assess for therapeutic 
response.   
 Improved understanding for how to compare and assess Crohn’s inflammatory 
burden 
 Improved systematic assessment of important complications 
 Improved ability to track and understand the natural history of Crohn’s disease. 
 
Methods 
 The SAR Crohn’s Disease-focused Panel was established in March 2014 to disseminate 
knowledge and improve the quality and availability of small bowel and Crohn’s disease imaging 
techniques, with an overall aim to improve the care of patients with Crohn’s disease.  After 
approval from the SAR Board of Directors and the AGA Institute Council, this panel met with 
representatives from the American Gastroenterology Association’s Imaging and Advanced 
Technology (AGA_IAT) section in person, via e-mail, and through conference calls, to develop a 
shared understanding of imaging findings across enterography techniques and their physiologic 
substrates.  Representatives with expertise in Crohn’s disease were also sought and included 
from the European Society of Gastrointestinal and Abdominal Radiology (ESGAR), the Society 
for Surgery of the Alimentary Tract (SSAT), American Society of Colon and Rectal Surgeons 
(ASCRS) and the North American Society for Pediatric Gastroenterology, Hepatology and 
  
Nutrition (NASPGHAN).  Through electronic communications and conference calls, consensus 
guidelines were reached and submitted to the SAR Board and AGA Council for approval.   
A primary aim of this work was to define and describe key imaging findings that relate to 
the diagnosis, severity and type of Crohn’s disease involvement in the small bowel.  To this end, 
the evidence of Crohn’s disease inflammation for specific imaging findings at CT and MR 
enterography was evaluated according to the Grading of Recommendations Assessment, 
Development and Evaluation (GRADE) system for evaluation of diagnostic tests 
31-33
.  For this 
purpose, CT and MR enterography were not considered as stand-alone tests, but as part of an 
imaging strategy combined with clinical assessment and ileocolonoscopy 
31
.  Practical 
conclusions were reached relating to each imaging finding reviewed, with the quality of the 
evidence for each conclusion graded along a four-point scale (i.e., very low, low, moderate, high) 
based on consensus evaluation of the medical literature by panel members.  High-quality studies 
were those that enrolled consecutive patients in a clinically relevant cohort, with universal 
application of an endoscopic or histologic reference standard, clear blinding of readers, and site-
specific correlation between reference and reader findings.  Quality was downgraded if these 
criteria were not met, if there was substantial variation between studies without a clear 
explanation, or if there was major uncertainty about the effect of false positives and negatives.  
Based on these conclusions, recommendations for use of CT or MR enterography or 
incorporation of each imaging finding into a clinical report is given, with strong 
recommendations indicating confidence that incorporation will have desirable effects on patient 
outcomes and outweigh undesirable effects or alternatives 
34
.   The strength of the 
recommendation also takes into account alternative management strategies.  After approval of all 
guidelines by all authors, this document was submitted to the AGA Council, and the Board of 
  
Directors for SAR and the Society of Pediatric Radiology (of which 3 SAR Disease-focused 
Panel members are representative) for approval. 
 
Imaging Findings (Tables 1-3) 
 Table 1 defines and describes imaging findings of mural inflammation at CT and MR 
enterography, along with important diagnostic considerations and practical conclusions.  Figure 
1 pictorially illustrates an imaging-based morphologic construct that demonstrates the role of 
mural inflammation in driving Crohn’s disease exacerbations and response as seen at cross-
sectional enterography, and which will be explained in greater depth after individual imaging 
findings have been reviewed.  The pictorial representation of a single bowel loop is used to 
facilitate a unified understanding of how mural inflammation can change independent of signal 
properties of cross-sectional imaging modalities.   Multiple studies have shown that in patients 
with Crohn’s disease, imaging findings of inflammation are strongly associated with the 
presence of histologic inflammation
35-39
.  Evidence describing and supporting the use of these 
imaging findings for small bowel inflammation is provided in references within Table 1.  By 
extension and inference, similar findings can reflect enteric inflammation in the stomach and 
colon.   
While the co-existence of segmental hyperenhancement and wall thickening are used in 
combination as imaging findings reflecting Crohn’s disease inflammation 39, 40, a number of 
other conditions can result in these imaging findings even when segmental involvement is 
multifocal 
41, 42
.  Additionally, other imaging findings often seen in small bowel Crohn’s disease 
inflammation such as mural stratification and intramural edema can also be seen in a number of 
other conditions.  Asymmetric inflammation in the bowel wall in Crohn’s disease is commonly 
  
more severe along the mesenteric border and is probably a specific feature in Crohn’s disease 43 
(Fig. 2).  The co-existence of mural inflammation and penetrating complications should also 
suggest Crohn’s disease, in the absence of other known causes of penetrating complications such 
as appendicitis, diverticulitis, tumor, and tuberculosis.  Given these considerations, radiologists 
should diagnose inflammatory small bowel Crohn’s disease either (i) in known Crohn’s disease 
patients when the non-specific findings of inflammation are present, or (ii) when enteric 
inflammation is asymmetric or co-exists with the typical penetrating complications of Crohn’s 
disease.  In the absence of a clinical diagnosis of Crohn’s disease or asymmetric inflammation 
(with or without penetrating complications), radiologists should describe the location and length 
of non-specific small bowel inflammation.  Gastroenterologists can then correlate these non-
specific radiologic findings with endoscopic and other clinical data to guide further management. 
 In addition to describing the length of intestinal inflammatory involvement, radiologists 
should describe the severity of inflammation based on wall thickness, and presence of luminal 
ulcerations, and increased intramural T2 signal 
4, 22, 44, 45
 (Fig. 2).  Luminal ulcerations appear as 
small focal breaks in the intraluminal surface of the bowel wall with focal extension of air or 
enteric contrast into the inflamed bowel wall (Fig. 3).  Because Crohn’s disease itself, as well as 
physiologic factors and technical factors affecting acquisition, can affect the degree of bowel 
wall contrast-enhancement, hyperenhancement is a sign of active inflammation, but is not used 
to describe severity unless quantitative measures are utilized 
46
.  Mild inflammation is described 
when segmental hyperenhancement is present with minimal wall thickening of 3-5 mm and 
rarely causes luminal narrowing.  Severe inflammation is present if ulcerations or high T2 
intramural signal are identified (Fig. 3).  Restricted diffusion is a non-specific sign of Crohn’s 
disease mural inflammation, but when other typical findings of mural inflammation are present 
  
on contrast-enhanced and/or T2-weighted images, restricted diffusion is a complementary and 
supportive finding that has been shown to correlate with severe inflammation at endoscopy
24
.   
Restricted diffusion is present when intramural hyper intensity is present on high b-value images 
(often similar to reactive lymph nodes), and should prompt a careful assessment for other signs 
over severe inflammation.  Radiologists should be aware that false positives can be due to many 
factors including suboptimal fluid distention.   The diagnosis of active Crohn's disease should not 
be made on the basis of restricted diffusion alone, and that the normal jejunum demonstrates 
increased relative non-focal restricted diffusion in comparison to the normal ileum 
45, 47
.   
 Crohn’s disease strictures result from complex interactions between inflammatory cells, 
cytokines, mesenchymal cells, and enteric flora, and result in variable degrees of luminal 
narrowing 
48
.  The majority of Crohn’s disease strictures have both an inflammatory as well as 
fibrotic component due to repeated inflammation and reparative damage 
49, 50
, and estimating the 
relative contribution of inflammation, fibrosis, and smooth muscle hypertrophy in dominant 
strictures has been an area of active imaging investigation 
51, 52
.  However, there is no universally 
accepted clinical or histologic scoring system for stricture-related fibrosis 
48
.  Gastroenterologists 
and radiologists generally refer to different physical findings when identifying a stricture.  
Endoscopists generally think of luminal narrowing as a stricture.  Radiologists generally rely on 
the presence of proximal dilation (often defined as > 3 cm), as many bowel segments with 
Crohn’s-related inflammation demonstrate luminal narrowing, and cross-sectional imaging 
cannot assess luminal compliance or readily differentiate between spasm or fixed narrowing at a 
single time point.  Moreover, both predominantly fibrotic and predominantly inflammatory 
strictures can fail to respond to medical therapy and ultimately require surgical intervention.  
Several imaging techniques and findings such as magnetization transfer, ultrasound elastography, 
  
diffusion-weighted imaging and relative contrast enhancement on delayed MR imaging with 
gadolinium are actively being investigated for their ability to estimate fibrosis in Crohn’s disease 
strictures, but none of them have been validated.  However, multi-phase cinematic thick slab 
imaging with balanced steady state precession (e.g., true-FISP or FIESTA) can be helpful in 
detecting and increasing confidence in stricture presence at MR enterography 
53, 54
.  Until 
prospective studies validating the relationship of imaging findings to histologic fibrosis are 
completed and a consensus emerges, Crohn’s disease strictures can be reliably identified by both 
luminal narrowing and unequivocal upstream dilation in order to minimize false positive findings 
(Table 1) 
50
.   Fixed luminal narrowing without upstream dilation cannot reliably be diagnosed as 
a stricture on a single image, but when multiple pulse sequences, fluoroscopic observation, or 
serial imaging exams demonstrate fixed narrowing without upstream dilation, it is appropriate 
for radiologists should describe that a probable stricture is present.  Enteroclysis assessment can 
be helpful in equivocal cases as it is more sensitive for stricture presence.  Radiologists and 
clinicians should be aware that when strictures are in close proximity to each other, the ability to 
radiographically detect downstream small bowel strictures is compromised, as an upstream 
stricture is already causing an obstruction.   
Following stricture identification, radiologists should state whether findings of 
inflammation are present or absent within the stricture (Fig. 4).  Findings of inflammation within 
a stricture are critical as current medical treatments can alleviate inflammation and avoid or 
delay surgery, while true fibrotic strictures are likely to require strictureplasty, excision or 
endoscopic bowel dilation.  Additionally, strictures should be evaluated for symmetry, nodularity 
or extension of soft tissue into the adjacent mesentery that may signal development of a 
neoplasm 
55
.  Radiologists should report the number, location and length of Crohn’s disease 
  
strictures in patients so that gastroenterologists and surgeons can decide on the best therapeutic 
option and approach.  While it is understood that the degree of bowel dilation proximal to a 
stricture is a result of many factors including chronicity and ingested material, the degree of 
upstream dilation is often useful to endoscopists and surgeons in deciding if treatment is 
warranted, or which strictures to treat, if multiple strictures are present.  The combination of 
presence/absence and severity of inflammation, stricture length, and degree of upstream dilation 
and fistulas can provide clinicians with necessary information for treatment decisions 
56
. 
 Table 2 summarizes imaging findings in penetrating complications and mesenteric 
findings in Crohn’s disease.  Penetrating complications result from transmural inflammation and 
include sinus tracts, fistulas, inflammatory masses abscesses, and rarely, free intraperitoneal 
perforation.  Sinus tracts can be blind-ending in the mesentery, terminate at fascial planes, or 
extend longitudinally within the bowel wall.  Fistulas should be described by the two epithelial 
structures they connect (e.g., enteroenteric, enterocolic, enterocutaneous, rectovaginal, or 
enterovesical).  Enteric fistulas within the abdominal cavity should be described as simple or 
complex similar to perianal fistulas 
57
.  Complex, asterisk-shaped fistula complexes are often 
seen that tether multiple loops of small bowel and/or colon (Fig. 5).  Inflammatory mass 
describes dense inflammatory mesenteric inflammation adjacent to severe mural inflammation or 
penetrating complications that is not an abscess and does not have a well-defined fluid 
component.  The term “phlegmon” should not be used.  It should be noted that clinical 
experience and the pathologic literature supports the strong association between stricture 
formation and penetrating disease 
28, 29
.  Thus, when penetrating disease is present, visual 
inspection should be directed at the site of fistula origin for an inflamed and stenotic bowel 
segment with upstream dilation, as these are nearly always present.  Conversely, the proximal 
  
end of inflamed and stenotic bowel segment should be scrutinized for detection of penetrating 
complications as most arise from that part of the involved segment.  We acknowledge that a 
weakness of the current proposal is that some inflamed small bowel segments giving rise to 
fistulas will not cause proximal small bowel dilation as the upstream pressure gradient causes 
decompression through the fistula rather than dilation of the proximal bowel; these segments 
would not be identified or termed “strictures” based on a strict interpretation of our proposed 
scheme.   However, because the evidence is overwhelming, when a complex fistula is seen to 
arise from a small bowel segment with active inflammation, and no upstream dilation is present, 
one might consider an impression in the clinical report such as, “complex penetrating disease 
with active inflammatory small bowel Crohn’s disease with luminal narrowing; stricture with 
imaging findings of active inflammation highly likely.” 
Because approximately one-quarter of Crohn’s disease patients present with an anorectal 
fistula, complete imaging of the anal sphincters and perineum is imperative for every CT and 
MR enterography exam (Fig. 6).  Artifacts often occur over the anus due to the placement of 
exterior phased-array coils at MR enterography, but adequate anal imaging can be performed in 
such cases using the body coil that is intrinsic to the magnet itself.  It has been demonstrated that 
evaluation of the anorectal structures is best done with a pelvic magnetic resonance imaging 
(MRI) with a dedicated perianal fistula protocol
58.  In clinical care, gastroenterologists often are 
most interested in the presence or absence of a perianal fistula or abscess; detailed fistula 
anatomy is often not required.  In the absence of an abscess, therapy with immunosuppressive or 
biologic medications can proceed, whereas an abscess will require antibiotic treatment and/or 
drainage prior to the initiation or continuation of therapy, depending on its size.  The question of 
the presence or absence of an anorectal abscess can typically be answered with CT or MR 
  
enterography.  It should be noted that perianal disease is not considered penetrating disease in 
either this guideline or the Paris classification
26
. The mechanism of perianal disease is distinctly 
different than that of classic penetrating disease 
59
.  In addition to the anus and colorectum, 
radiologists should carefully inspect the appendix, as it is frequently involved with ileocolonic 
Crohn’s disease 60, 61, and appendicitis is rarely the first presentation of Crohn’s disease.   
Imaging findings of appendiceal Crohn’s disease involvement are similar to those in the small 
bowel, and ileal-appendiceal fistulas are consequently not uncommon. 
 The spectrum of mesenteric vein thrombosis or occlusion has recently been described in 
Crohn’s disease patients 62, 63.  Radiologists should evaluate for and distinguish between acute 
mesenteric thrombosis and sequela from prior thrombosis, sometimes referred to as chronic 
mesenteric vein thrombosis, but more accurately termed chronic mesenteric venous occlusion.  
Acute portal and superior mesenteric vein thrombus can be seen in Crohn’s disease patients as a 
hypoattenuating thrombus, expanding the vein.  These thrombi have been observed to generally 
resolve without anticoagulation.  However, peripheral mesenteric venous thrombi frequently 
evolve into chronic peripheral mesenteric venous occlusion on follow-up imaging, with 
segmental pruning of the mesenteric arcade with development of collateral pathways or small 
bowel varices.  Chronic peripheral mesenteric venous occlusions typically correspond 
anatomically to small bowel segments with active or prior Crohn’s disease inflammation (Fig. 7).  
Coronal imaging with maximum intensity projections are especially helpful in visualizing the 
mesenteric venous arcade.  Acute and chronic mesenteric venous thromboses have been 
correlated to increased risk for stricture or surgery in a retrospective series 
63
, but their impact on 
the natural history of disease is poorly understood. 
  
 Table 3 lists extra-intestinal findings related to Crohn’s disease (or Crohn’s disease 
therapies) that should be searched for in every CT and MR enterography exam.  The most 
clinically important findings are sacroiliitis, primary sclerosing cholangitis (PSC) and avascular 
necrosis (AVN), most often involving the femoral heads.  Many patients with Crohn’s disease 
complain of low back pain.  Identifying the changes of sacroiliitis identifies the cause and 
facilitates therapy.  Early PSC is often first identified on enterography, and is manifest by the 
presence of discontinuous, intrahepatic bile ducts that do not connect to non-dilated central ducts.  
Once identified, the patient can be followed more closely for complications of PSC, typically 
with MRI/magnetic resonance cholangiopancreatography (MRCP) and endoscopic retrograde 
cholangiopancreatography (ERCP).  Lastly, identifying AVN will again assist the care of a 
patient with hip pain and prompt avoidance of steroids when possible.   
 
Characterization of Disease Activity 
 Table 4 lists recommendations for clinical practice based upon the evidence for specific 
imaging findings.  Each recommendation is accompanied by a description of the strength of the 
recommendation (i.e., strong vs. weak), with strong recommendations having anticipated 
desirable effects on patient outcomes 
34
.  These recommendations set forth imaging criteria for 
the imaging diagnosis of Crohn’s, as well as describing its severity and complications at CT and 
MR enterography.  Furthermore, they recommend cross-sectional enterography be performed at 
diagnosis to detect small bowel involvement that may not be identified by other methods, and 
recommend it be considered in disease monitoring when small bowel disease or penetrating 
complications are present (Fig. 8).   
  
Table 5 lists recommended impressions in radiology reports for summarizing imaging 
findings and grouping them into recognized patterns of disease in a manner that is useful to 
referring physicians, and accounts for exacerbations and response to therapy as seen at cross-
sectional enterography (Fig. 1).  This imaging-based morphologic construct comes from an 
observation of the dynamic nature of Crohn’s inflammation.  As observed by Cosnes and 
Lemann 
25, 64
, active inflammation is thought to eventually progress to stricturing and penetrating 
disease complications in a high proportion of patients, with some patients presenting with 
penetrating or stricturing disease complications, which may portend a more aggressive course.  
With mild inflammation, wall thickening and hyperenhancement is often seen without luminal 
narrowing.  As inflammation progresses and becomes more severe, enterographic images may 
display increased intramural T2 signal, restricted diffusion and ulcer formation in conjunction 
with luminal narrowing.  Adoption of a consistent and well-defined reporting mechanism that 
links imaging findings of inflammation, stricturing disease and penetrating complications with 
estimates of disease severity will facilitate selection of optimal therapies and communicate 
disease progression and reversibility 
65
, and directly parallel similar linkages provided in the 




Several terms should be used in describing the pathophysiological significance of 
imaging findings associated with current or prior small bowel inflammation.  Active Crohn’s 
disease inflammation should be identified based on the pre-defined criteria, as should non-
specific inflammation.  Active inflammation may respond to medical therapy.  When no imaging 
findings of active inflammation are identified in patients with suspected Crohn’s disease, this 
should be explicitly stated in the radiologic report.  Complete resolution of small bowel or 
  
colonic inflammatory findings can occur in Crohn’s disease patients, with the bowel returning to 
a normal appearance.  In these cases, it is also correct to report that no small bowel inflammation 
is seen.  Partial response to medical therapy may be indicated by a decrease in the severity of 
imaging findings within an inflamed segment, or evolution to much shorter and patchy areas of 
involvement over the length of the involved segment (Fig. 1) 
12
.  Alternatively, inflammation 
may resolve with residual findings such as asymmetric fat deposits within the small bowel wall, 
residual pseudosacculation and scarring, or mild wall thickening, without luminal narrowing or 
other morphologic or signal changes reflecting active inflammation (i.e., absent T2 signal 
hyperintensity, hyperenhancement, restricted diffusion).  When sequelae of prior inflammation 
are present without active inflammation, “Crohn’s disease with no imaging signs of active 
inflammation is present” should be stated in the conclusion of the report.  Terms such as 
“quiescent” or “chronic” are discouraged as their meaning may be erroneously interpreted, 
especially by patients who now, in many institutions, have access to their imaging reports.  .  
Gastroenterologists and patients making clinical decisions based on imaging findings should be 
aware that active vs. inactive disease based on imaging criteria does not always equate to 
histologically, endoscopically or clinically active or inactive disease.  There is a relationship 
between these assessment modalities, but the properties assessed with different modalities vary.  
Stricture formation occurs when there is focal or segmental luminal narrowing with 
unequivocal upstream dilation.  Imaging findings of concomitant active inflammation are most 
often present 
49, and we have termed this pattern “stricture with findings of active inflammation” 
(Figs. 1 and 4).  Strictures without imaging findings of inflammation may also exist.  In this 
situation, the bowel wall is thickened without other imaging findings of inflammation.  Adler et 
al. found that such strictures did not have more fibrosis than strictures with inflammation, and 
  
lack of imaging findings of inflammation did not imply that histologic inflammation was absent 
30
.  While there is a paucity of published data on the subject, in the experience of the radiologist 
co-authors, penetrating disease has not been seen to arise in the setting of a stricture without 
inflammation.  Imaging criteria for fibrosis are currently being developed and evaluated 
50, 52
.   
Internal, penetrating disease (not perianal disease) may occur at any time point during the 
course of the disease, but occurs overwhelmingly in patients with strictures associated with 
active inflammation.  Sinus tract and fistula formation, abscess, and free perforation are all 
findings of penetrating disease.  Fistulas may be simple or complex.  Simple fistulas are 
comprised of a single tract connecting a bowel loop to adjacent bowel or other structures such as 
the urinary bladder.  Complex fistulas connect multiple adjacent bowel loops or structures.  With 
both simple and complex fistulas, the bowel loops affected are often angulated and appear 
tethered by the fistula tract (Fig. 5).  Furthermore, it is common to see small, interloop abscesses 
along the course of these complex fistulas.  If no active inflammation is associated with a fistula, 
this should also be stated.  Post-operative fistulas are often not associated with inflammation, but 
obviously arise at or near the site of anastomoses.  
Colonoscopy is considered the reference standard for colorectal inflammation.  This 
guideline only addresses small bowel Crohn’s disease and complications frequently seen on CT 
and MR enterography in these patients.  A comprehensive guide for describing colorectal 
inflammation at cross-sectional imaging is beyond the scope of this work, as we considered CT 
and MR enterography as part of an imaging strategy combined with clinical assessment and 
ileocolonoscopy.  Transabdominal ultrasound (with or without intravenous contrast) and video 
capsule endoscopy are used at many institutions in the diagnosis and surveillance of Crohn’s 
disease, and their role in clinical management continues to evolve; however, integration of their 
  
imaging findings is also beyond the scope of this work, which focuses on exclusively on CT and 
MR enterography for small bowel Crohn’s disease. 
 
Structured Reporting 
 Structured reporting templates are used by many radiologic practices for specific clinical 
scenarios to insure important clinical information is always captured in a systematic fashion.  
They have been shown to improve the quality of information conveyed to referring clinicians 
66
.  
Several groups have advocated for structured reporting for CT and MR enterography.  Table 6 
demonstrates a structured cross-sectional enterography report, and is adapted from Baker et al 
7
.   
 
Conclusion 
 CT and MR enterography can provide key information to guide treatment relating to the 
presence, severity, and extent of Crohn’s disease and its complications that is not available from 
clinical and endoscopic evaluation, for both adult and pediatric patients.  This guideline 
establishes a common expectation of structures that can be systematically evaluated in 
enterographic images, a shared understanding of imaging findings, and agreed upon terms for 
describing imaging findings in Crohn’s disease.  A shared approach for linking specific imaging 
findings to clinically useful impressions can be used to better guide therapeutic decision-making 
in the short-term, and improve our understanding of the natural history of long-term 
complications of Crohn’s disease.  As imaging techniques, new therapies, and a better 
understanding of the Crohn’s disease pathophysiology are developed, this shared approach can 
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Table 1.  Imaging findings associated with small bowel Crohn’s disease inflammation.  Bold items are required descriptive terms that 
should be used when present.  Conclusions are based on criteria identified in the Methods, with the level of evidence summarized 
accordingly as very low, low, moderate or high.  
 
Imaging Findings Description/Definition DDX 
Considerations/Comments 
Conclusions 




intensity on contrast-enhanced 
scan in non-contracted segment 
in comparison to nearby normal 
small bowel segments 




 Causes include Crohn’s 
disease-related mural 
inflammation, backwash 
ileitis, infectious enteritis, 
mucositis, graft vs. host 
disease, contraction or 
underdistension, radiation 
enteritis, NSAID enteropathy, 
angioedema, vasculitis, and 
ischemia.   
 Altered enhancement in 
Crohn’s disease can also 
reflect processes other than 
inflammation such as fibrosis 
or chronic mesenteric venous 
occlusion 
 More likely indicates Crohn’s 
disease when asymmetric and 
combined with other mural 
and mesenteric findings below 
1.  Segmental mural 
hyperenhancement and wall 
thickening have a moderately 
high sensitivity and specificity 
for small bowel Crohn’s disease 





2.  Mural hyperenhancement 
without wall thickening is a non-
specific imaging sign, and may 
reflect inflammation or other 
processes. (Moderate) 
23, 36, 39, 40
 
 
3.  CT and MR enterography 
may detect small bowel 






4.  CT and MR enterography 
with oral contrast only will not 
detect or stage colonic 











     Asymmetric Asymmetric in cross-sectional or 
longitudinal direction compared 
to the lumen.  Mesenteric border 
is often more affected than anti-
mesenteric border 




 Can refer to morphologic 
pattern of hyperenhancement, 
wall thickening or 
stratification 
     Stratified (Bi- or 
Tri- Laminar) 
Inner-wall hyperenhancement or 
halo sign 
 In Crohn’s disease, can be due 
to submucosal edema, 
intramural fat deposition or 
inflammatory infiltration 
  
 Can also be due to other 
causes of segmental mural 
hyperenhancement above 
 “Mucosal hyperenhancement” 
is erroneous descriptor as 
mucosa is often absent at 
endoscopy in inflamed loops 
with stratified segmental 
hyperenhancement 
 Intramural fat indicates 
chronicity and is unrelated to 
whether inflammation is 
present or not 
 Intramural edema indicates 
active inflammation if due to 
Crohn’s disease 
 At this time, no clinical 
significance is attributed to 
either the bi- or tri-laminar 
pattern; the tri-laminar pattern 
is more often identified on 
contrast enhanced MR, likely 
owing to its superior contrast 























5.  Hyperintense T2-weighted 
signal and restricted diffusion at 
MR enterography is correlated 






6.  Unenhanced MR 
enterography with diffusion-
weighted imaging has a 
moderate sensitivity and 
specificity for detection of ileal 




      Homogeneous, 
symmetric 
Transmural hyperenhancement  Can be due to many causes 
including edema, collagen 
deposition, infiltration, 
ischemia, shock bowel 
   
Wall Thickening   Only measured or estimated in 
bowel loops distended by 
enteric contrast 
 Measure the thickest portion 
of most distended segment or 
site of most severe 
inflammation 
     Mild 3 - 5 mm 
22, 23, 25, 40
  
     Moderate  5 - 9 mm  
  
     Severe ≥ 10 mm 
21
   Look for signs of tumor for 
focal stenoses > 1.5 cm in 
diameter—mass, extension 
into adjacent mesentery, etc… 
3, 76, 77
 
Intramural edema Hyperintense signal on fat-
saturated T2-weighted images; 
only on MR (cannot comment on 




 In comparison to normal small 
bowel.  
 Increased hyperintensity on 
T2-weighted images is 




 In regions of Crohn’s disease-
related inflammation on 
gadolinium-enhanced images, 
increased diffusion-weighted 
signal abnormality is 





Stricture Luminal narrowing in area of 
Crohn’s disease: 
  With unequivocal upstream 
dilation  
 
 Location and length should be 
described for potential 
subsequent surgical or 
endoscopic intervention 
 Remember that strictures also 
arise from NSAID and 
radiation enteropathy, and 




7.  Most Crohn’s disease 
strictures have both 
inflammation and fibrosis. 
(High) 
21, 49, 50, 52
 
 
8.  A stricture is present when 
the lumen is narrowed, and there 
is proximal small bowel dilation. 
(High) 
30, 49, 50, 68, 79
 
 
9. Proximal small bowel dilation 
may correlate with a higher 
burden of fibrotic disease.  
(Low) 
21, 30, 49, 50, 80
 
 
10.  CT and MR enterography 
can detect unsuspected small 
bowel strictures in Crohn’s 
disease patients. (Low) 
10, 81
 
     without upstream 
dilation 
 Upstream lumen < 3 cm 
 When multiple pulse 
sequences, fluoroscopic 




upstream dilation, it is 
appropriate to describe 
that a probable stricture 
is present 
 Degree of upstream dilation 
can be highly variable based 
on many factors including 
chronicity, ingested material, 
etc… 
 Focal reduction in luminal 
diameter despite adequate 
enteric contrast in a bowel 
loop with imaging findings of 
Crohn’s disease  
  
    with mild upstream 
dilation 
Upstream lumen = 3- 4 cm  
    with moderate to 
severe upstream 
dilation 
Upstream lumen > 4 cm  When present, careful 
assessment of the transition 
point should be performed in 
order to determine the cause of 
the bowel obstruction. 
Differential diagnosis includes 
mixed stenotic and active 
inflammatory Crohn’s disease, 
adhesive disease and tumor; 
when moderate to severe may 
be appropriate to state in 
Impression “small bowel 
obstruction” 
    
Ulcerations Appear as small focal breaks in 
the intraluminal surface of the 
bowel wall with focal extension 
of air or enteric contrast into the 
inflamed bowel wall.  Do not 
extend beyond the bowel wall 
 When seen at cross-sectional 





 Avoid the term “penetrating 
ulcer” so that it is not confused 
with penetrating disease such 
as fistula or abscess 
 If transmural, useful in 
Lemann score 
11.   Visualization of ulcers at 
cross-sectional enterography is a 
marker of severe inflammation.  
(High) 
4, 19, 22, 82
 
Sacculations Broad-based outpouchings that 
occur along the anti-mesenteric 
border due to acute or chronic 
mesenteric border inflammation 
 Sequela of asymmetric mural 
inflammation with shortening 
of the gut along the mesenteric 
border 
 
Diminished motility Alerts radiologist to locations of 
potential disease 
 Rely on conventional imaging 
features of intestinal 
inflammation for diagnosis 
and severity assessment 
 Cine true-FISP imaging can 
display peristalsis and may be  
helpful in improving 
confidence that inflammation 
is absent 
12.  Altered motility can be 






Table 2.  Imaging findings of penetrating disease and mesenteric inflammation in Crohn’s disease. 
 
Imaging Findings Description/Definition Comments Finding 
FISTULAS    
Simple fistula Appears as an extra-enteric tract, 
with or without internal air or 
fluid 
87
; affected loops are often 
angulated or tethered 
88
 
 Fistulas should be 
described by bowel 
loop  origin and 
structure to which 
they connect 
 Usually arise from 
within or just 
proximal to a stricture 
28, 29
 
 Usually arise proximal 




operative leak in 
addition to fistulizing 
Crohn’s disease when 
examining extra-
enteric tracks 
originating in the 
region of enteric 
anastomoses 
13.  CTE and MRE have similar 
and moderately high accuracy for 
penetrating Crohn’s disease 





14.  Penetrating complications 
detected at CT and MR 
enterography may occur in 






Complex Fistulas Multiple tracts often forming an 
asterisk-shaped or “clover-leaf” 
appearance, or “star sign”; 
affected loops often angulated or 
tethered; an interloop abscess or 




Sinus Tract Wall defect that extends outside 
bowel wall  but not to adjacent 
organs or skin (usually 
  
  
accompanied by angulation and 
tethering of adjacent bowel or 
urinary bladder) 
Perianal fistulas Arise from rectum or anus and 
extend to skin in perineal region 
or vagina 
 Describe according to 





dedicated pelvic MR 
for assessment prior to 
surgical intervention 
or for activity 
assessment 
 Imaging of the anus 
mandatory part of any 
CT or MR 
enterography exam 
 About one-quarter 
present at or before 
time of Crohn’s 
disease diagnosis 
 Incidence varies by 




15.  Pelvic MRI is the most 
accurate test for the detection and 
characterization of perianal 
Crohn’s disease, but every CTE 
and MRE should image the anal 




Inflammatory Mass Ill-defined mass-like process of 
mixed fat and/or soft tissue 
attenuation/signal intensity (not 
water attenuation/signal 
intensity) usually associated with 
penetrating disease such as 
complex fistulas 









Fluid Collection with rim 
enhancement and/or internal air 
 May be difficult to 
distinguish from 





Increased attenuation (CT) or 
high T2 signal or restricted 
diffusion (MR) in mesenteric fat 
adjacent to abnormal bowel 
loops; if perirectal, then 
 Often associated with 
mesenteric border 
inflammation.   







Engorged vasa recta Engorged vasa recta that supply 
an inflamed bowel loop (“comb 
sign” 43) 
 May be a marker of 
inflammation but may 





Increased fat adjacent to 
abnormal bowel, displacing 
bowel loops; usually along 
mesenteric border, but can be 
circumferential  






 If acute, an intraluminal 
thrombus is seen 
 If chronic, narrowed 
central mesenteric veins 
are seen, with dilated 
peripheral collaterals 
forming via mesenteric 
branches and small 
bowel varices. If 
chronic suggest using 
term chronic mesenteric 
venous occlusion 















16.  Acute mesenteric vein 
thromboses and chronic 
mesenteric vein occlusions can be 
detected at CT and MR in 
Crohn’s disease patients, and may 





Adenopathy Lymph node > 1.5 cm in short 
axis 
 Reactive 
lymphadenopathy 1 – 
1.5 cm in short axis 
diameter is considered 





Table 3.  Extra-intestinal findings relevant to Crohn’s disease and seen at CT and MR enterography. 
 
Imaging Findings Description/Definition Comments 
Sacroiliitis Subtle erosions to frank fusion of SI joint, 
including increased T2 signal, subchondral 
marrow edema or enhancement; contrary 
to dogma, this is often asymmetric with 
only one side affected or one side more 
affected than the other 
 
Primary sclerosing cholangitis (PSC) Discontinuous, intrahepatic biliary ductal 
visualization and/or extrahepatic ductal 
wall thickening / enhancement without 
significant upstream dilation 
 
Avascular necrosis Focal sclerosis along the anterior aspect of 
the femoral head, best seen on coronal 
views with bone windows 
Describe if articular collapse is present or 
not 
Pancreatitis Can be medication-induced, due to 
cholelithiasis or idiopathic duct centric 
pancreatitis (steroid-responsive 
pancreatitis; formerly type II autoimmune 
pancreatitis) 
 
Nephrolithiasis & cholelithiasis 
102
  Describe presence and burden 
Cutaneous findings Including pyoderma gangrenosum, 
erythema nodosum or cutaneous vasculitis 
Can be seen in multiple locations (e.g., 




Table 4.  Recommendations for use of CT or MR enterography, and incorporation of imaging findings into the clinical report.  
A strong recommendation indicates confidence that the desirable effects of the test or interpretation will result in a positive impact on 
patient care.  A weak recommendation indicates that uncertainty exists relating to the positive and negative impacts on patient care. 
1. Radiologists should indicate that inflammatory small bowel Crohn’s disease is likely when either (i) in known Crohn’s patients 
when mural hyperenhancement and wall thickening are present, or (ii) when enteric inflammation is asymmetric or co-exists 
with the typical penetrating complications of Crohn’s disease.  (STRONG) 
2. Radiologists should report the number of involved bowel segments, approximate location (proximity to ileocecal valve or 
ligament of Treitz), length and degree of upstream dilation of Crohn’s strictures so that gastroenterologists and surgeons can 
decide on the best therapeutic option and approach. (STRONG) 
3. When describing bowel loops having a Crohn’s stricture or penetrating disease (sinus tract, abscess or enteric fistula), 
radiologists should state if imaging findings of mural inflammation are present (STRONG). 
4. Cross-sectional enterography should be performed at diagnosis of Crohn’s Disease to detect small bowel inflammation and 
penetrating complications beyond the reach of standard ileocolonoscopy.  (STRONG) 
5. Cross-sectional enterography should be considered in disease monitoring paradigms when small bowel disease or penetrating 
disease complications are present.  (STRONG) 
6. Dedicated pelvic MR (Perianal fistula MRI protocol) is required for the adequate preoperative assessment of perianal Crohn’s 
disease and its complications (number of fistula tracts, location and relationship to anal sphincter muscle complex, and 
presence of abscess), but every CTE or MRE should image the anus, and radiologists should comment if findings suspicious 
for perianal disease (fistula or abscess) are present.  (STRONG) 
7. Because intramural T2 hyperintensity, restricted diffusion, peri-enteric stranding, wall thickness and mural ulcerations seen at 
cross-sectional enterography generally correlate with severity of endoscopic and histologic inflammation, radiologists should 
comment on these findings and describe them when present.  (STRONG) 
8. MRE should be used rather than CT enterography, when possible, for estimating response to medical treatment in 
asymptomatic Crohn’s disease, as its multiparametric nature permits evaluation of multiple imaging parameters that reflect 
inflammation and avoids radiation.  (WEAK) 
9. If cross-sectional enterography is indicated and IV contrast cannot be administered, non-contrast MR enterography with T2-
weighted and diffusion-weighted imaging should be used an acceptable alternative. (WEAK) 
  
10. CTE and MRE exams should be carefully evaluated for evidence of mesenteric venous thromboses or occlusions and small 
bowel varices. (STRONG) 
  
  
Table 5. Recommended impressions summarizing imaging findings of small bowel Crohn’s disease at CT and MR enterography.  
Colonoscopy is considered the reference standard for colorectal inflammation.  Recommendations for CT and MR enterography 
descriptions of colorectal inflammation are not provided, but can parallel descriptions of small bowel inflammation, stricture and 
penetration. 
 
Impression Imaging Findings Comment 
Inflammation 
Non-specific small bowel inflammation 
 
    
 
Active Inflammatory Small Bowel 
Crohn’s disease  
-Without Luminal Narrowing 












Crohn’s disease with no imaging signs of 
active inflammation (known prior active 
inflammatory Crohn’s disease with 




 Segmental hyperenhancement 
and/or wall thickening in a patient 
without known Crohn’s disease  
 
 Asymmetric wall thickening, 
hyperenhancement and mural 
edema (i.e., intramural T2-
weighted signal) are specific for 
Crohn’s disease involvement. 
 Ulcers, wall thickening, restricted 
diffusion and perienteric stranding 
indicate more severe disease 
 Asymmetry is not required at sites 
of known prior disease or in a 
known Crohn’s disease patient 
 
 
 Imaging findings of inflammation 
are absent 
 Patchy intramural fat or residual 
pseudosacculation/scarring without 
inflammation may be seen 
 
 Imaging findings of inflammation 
 
 Please see segmental 
hyperenhancement in Table 1 
above for differential diagnosis 
 
 Describe sites, lengths, and add 
descriptors representing severity 
 Compare lengths and severity of 
disease if assessing for disease 
response or progression 
 Severe inflammation is manifested 
by ulcerations, marked T2-
weighted signal hyperintensity and 
restricted diffusion, and severe wall 
thickening 
 Mild disease is manifested by 
hyperenhancement, mild wall 
thickening, and absence of severe 
signs of inflammation  
 
 Mural healing can only be 
described when the present study 
demonstrates a normal bowel 




No imaging signs of active inflammation 
 
are absent   
Stricture 










Without imaging findings of active 
inflammation 
 
 Persistent luminal narrowing in 
area of Crohn’s disease with 
upstream dilation  
 Accompanying imaging findings of 
active inflammation 
 Consider adding “with small bowel 
obstruction” if upstream dilation 
moderate to severe 
 
 Persistent segmental luminal 
narrowing with upstream dilation 
 Wall thickening is present, but with 




 Describe locations and lengths of 
strictures and degree of obstruction 











Penetrating Crohn’s Disease  
 
(added in addition to determination of 
inflammatory Crohn’s disease and 
stricture) 
 
 Fistula and/or sinus tract; 
inflammatory mass; abscess; free 
perforation  
 Describe location and type, as well 
as association with Crohn’s disease 
stricture or inflamed bowel 
segment. 
 State if fistulas are simple or 
complex 
 Carefully examine for asterisk-
shaped fistulas complexes  
 
Perianal Crohn’s Disease  Perianal fistula – simple, complex 
 Perianal abscess – present/absent 
 Describe perianal disease including 
associated abscess with size 






 Recommend consideration of 
pelvic MRI 
Other complications  Mesenteric venous thrombosis or 
occlusion, AVN, PSC, sacroiliitis, 
pancreatitis, neoplasm, 









MR or CT Enterography with intravenous contrast 
 






 Disease location (stomach, duodenum, jejunum, mid or distal ileum, terminal ileum, colon, rectum, anus) 
 Number of diseased segments  
 Type(s) of disease (if all segments have similar findings then report once; if one or more segments are different then report 
each separately)  
o Inflammation 
 Describe imaging findings of inflammation (hyperenhancement, enhancement pattern, bowel wall thickening, 
intramural edema, ulcerations, restricted diffusion) 
 Describe location, length and severity (see Table 1), and describe stability or increase or decrease compared to 
prior studies 
 Other mesenteric findings (e.g., mesenteric vein thrombosis, perienteric edema, comb sign, fibrofatty 
proliferation) 
o Stricture 
 State if imaging findings of inflammation is/are present 
 Describe location and length 
 Describe degree of upstream dilation (mild <4 cm, moderate to severe ≥ 4 cm) 
o Penetrating complications – describe sinus tract, fistula, inflammatory mass, abscess or perforation 
 Site 
 Complexity 
 Relationship to inflamed bowel or stricture 
o Perianal Disease 
 Site 
 Complexity/classification 
 Associated abscess – presence or absence 
  
o Response to therapy 
 Compare to earlier exams to describe resolution or exacerbation of inflammatory findings 
 Extra-intestinal findings - sacroiliitis, AVN, PSC, cholelithiasis, nephrolithiasis, 
 Other complications or unrelated findings – e.g., chronic mesenteric vein thrombosis 
 
Impressions (add modifiers as shown in Table 4): 
 Inflammation statement:  If inflammation is present, specify location and length, estimate severity or change 
o Non-specific small bowel inflammation  
o Active inflammatory small bowel Crohn’s disease (± luminal narrowing) 
o Crohn’s disease with no imaging signs of active inflammation 
o No imaging signs of small bowel inflammation  
 Stricture Statement: 
o Stricture with signs of active inflammation – specify length of stricture and degree of proximal obstruction 
o Stricture without signs of active inflammation - specify length and degree of proximal obstruction 
 Penetrating Statement – describe type of fistula, simple or complex, and other penetration, and association with strictures 
and enteric inflammation 
 Perianal fistula (if present) 




Fig. 1 -Imaging-based morphologic construct that demonstrates the role of mural inflammation 
in driving small bowel Crohn’s disease and its stricturing and penetrating complications.  Mild 
non-specific mural inflammation can progress into asymmetric disease with greater and more 
characteristic mucosal and mural inflammation.  Similarly, small bowel loops affected by active 
inflammatory small bowel Crohn’s disease can progress to stricturing and penetrating 
complications, revert to normal in appearance, or have residual sequela of prior inflammation 




Fig. 2 – Asymmetric imaging findings of inflammation are characteristic of active 
inflammatory small bowel Crohn’s disease and occur most prominently along the mesenteric 
border.  CT enterography images show patchy mesenteric border inflammation in the terminal 
ileum (top left, arrows), which nearly completely resolves after patient received combination 
therapy over one year (top right).  Another patient demonstrates marked inflammation along the 
mesenteric border with wall thickening and hyperenhancement (bottom left, arrows), engorged 
vasa recta and restricted diffusion (bottom left, inset).  A third patient shows findings of 
asymmetric involvement with mesenteric border wall thickening (bottom right, white arrow) and 





Fig. 3 – Imaging findings of severe small bowel inflammation at MR and CT enterography in 
three different patients.  Top row shows substantial wall thickening, intramural edema on T2-
weighted fat-saturated image, restricted diffusion, and small ulcerations on gadolinium enhanced 
images.  Middle row shows findings of inflammation with wall thickening with ulcerations, 
intramural fat on enteric phase imaging indicating chronicity, and persistent layered 
enhancement indicating active inflammation on delayed imaging.  Bottom row shows CT 
enterography images demonstrating severe inflammation with marked wall thickening and 




Fig 4. – Imaging findings of small bowel strictures in Crohn’s disease patients.   Coronal image 
from CT enterography in patient with prior ileocecectomy demonstrates short segment stenosis 
(top left, arrow) without imaging findings of inflammation, with subsequent endoscopy not 
identifying any evidence of mucosal inflammation either.  Two jejunal strictures in another 
patient (top middle and right, arrows) with proximal small bowel dilation (top middle and right, 
P) demonstrate imaging findings of inflammation with mural hyperenhancement and 
stratification with wall thickening.  Subsequent surgical resection demonstrated stricture 
formation with transmural inflammation in all layers of the bowel wall.  Bottom row shows small 
bowel dilation (bottom left, P) proximal to a long segment stricture with inflammation  (bottom 
middle and right, arrows), with single-shot fast spin-echo image showing wall thickening and 
ulceration (bottom middle, small arrow) and 7-minute delayed gadolinium image showing mural 




Fig. 5 – Coronal single-shot fast spin-echo images show a thickened ileal loop (top left, arrow) 
that is tethered and angulated to an asterisk-shaped fistula complex (arrowhead) involving 
multiple loops of ileum (I), sigmoid colon (S), cecal pole (C) and bladder (B).  An 
enterocutaneous fistula also connects to this fistula complex, but is not shown.   Note 
inflammation, as evidenced by hyperenhancement (bottom left) and restricted diffusion (bottom 
right), in the ileum and cecal pole (arrows). 
  
  
Fig. 6 – CT enterography performed to evaluate Crohn’s disease inflammation in patient with 
known enterocutaneous fistula demonstrates small perianal abscess adjacent to right puborectalis 
(left, arrow) and intersphincteric horseshoe ramifications (middle, arrows), with inferior 
ramification to left gluteal crease (top right, arrow).  The enhancement of the normal internal 
anal sphincter (middle, black arrow) permits differentiation from the surrounding external anal 
sphincter.  Patient subsequently underwent examination under anesthesia with drainage of 




Fig. 7 – Thick coronal maximum intensity projection images from CT enterography show typical 
findings of chronic mesenteric venous occlusion with narrowed peripheral mesenteric vein (top 
left, white arrows) and dilated peripheral marginal veins (top right and bottom left, white 
arrowheads) that return blood back to the portal system through collateral pathways.  Note distal 




Fig. 8 – CT enterography performed two weeks after normal ileocolonoscopy show that the very 
distal terminal ileum (top left, black arrow) appears normal, but moderate to severe asymmetric 
inflammation indicating Crohn’s disease is present in the more proximal terminal ileum for 
approximately 20 cm (top row, white arrow).  On bottom row in a different patient, MR 
enterography images demonstrate severe active small bowel inflammation (arrows) involving 
long segments of jejunum and ileum, but normal-appearing terminal ileum (arrowhead).  






Appendix.  Linkage between Lemann Index of Digestive Disease Damage & SAR Terms for 
Disease State (Impressions) 
 
 The Lemann Index or Score was developed to describe the digestive disease location, 
severity, extent, progression and reversibility of Crohn’s disease as measured by imaging 
findings and surgery. The scale is based upon three aspects: stricturing lesions, penetrating 
lesions and the history of surgery or any other interventional procedure. For each aspect, a grade 
is assigned from 0-3, and is summarized below 
25, 65
.   
 
Grade Stricturing Lesion Penetrating Lesion 
0 Normal Normal 
1 Wall thickening < 3 




2 Wall Thickening ≥ 3 





3 Stricture with 
Prestenotic Dilation 
Abscess or Fistula 
 
The endorsed Consensus terms for Disease State are analogous to the Lemann index , 
facilitating the transfer of imaging reporting into disease damage (below), the primary difference 
being that the Lemann index does not necessarily state that imaging findings of inflammation are 
present for grade 1 or 2 strictures.  For example, findings of prior inflammation such as 
intramural fat could cause wall thickening, which would be classified as grade 2 strictures using 
Lemann, and which would not be classified as active inflammation or strictures under the current 
proposal.  Additionally, the current proposal creates a stronger linkage to stricturing disease 
when penetrating complications are present. 
 
Consensus Disease State Lemann Stricture Grade Lemann Penetrating Grade 




without Luminal Narrowing 
1 Unlikely to occur 
(2 if deep transmural ulcers 
present; otherwise score of 0) 
Active Inflammatory with 
Luminal Narrowing 
2 2 if deep transmural ulcers 
present; otherwise score of 0 
Stricture with Active 
Inflammation 
3 2 if deep transmural ulcers 
present; otherwise score of 0 
Penetrating Disease 0 3 
 
 
